BRAF and metastatic melanoma: On 1 October 2015, ipilimumab in combination with nivolumab received FDA approval for BRAF V600 wild-type unresectable or metastatic melanoma based on CheckMate-069, a randomized, phase 2 study [29] (Category 1).